Express your opinion about this website:
Traffic report about herceptin.com - here you can find answers to questions like these:
The most recent time we have spotted herceptin.com on Alexa rankings was on February 11, 2014 (3,737 days ago) and then the ranking was 959,585. And this is the best position that herceptin.com ever had in Alexa.
The most recent time we have spotted herceptin.com on Quantcast list was on February 6, 2014 (3,742 days ago) and then the rank was 267,053. And this is a bit worse position than average position for herceptin.com in Quantcast.
Website is hosted on IP 72.34.128.114.
The host name of this IP address is trastuzumab.net.
There are 1 websites hosted on exact the same IP and 87 websites that are hosted on similar IP address.
We have no data about websites that could be similar to herceptin.com.
We've checked herceptin.com recently and it was online. The load time was 0.0359 seconds faster than average. The size of document was 18,392 bytes shorter than usually. The website contained 61 links less than the average.
We have no information if herceptin.com is optimised for mobile devices.
We did not encounter any safety threats while testing this website.
We did not find any data about herceptin.com being listed in the blacklists.
It seems that herceptin.com was never dropped before.
Click here to see the list of dropped domains
Our system found out that there could be 291 domains with the same beginning as herceptin.com
Our system found out that there could be 46 mistakes made in the typing process.
And here you'll find analysis of HTML code:
| PROPERTY | VALUE |
|---|---|
| Keywords: | herceptin, trastuzumab, breast cancer treatment, her2, her2 positive breast cancer, her2 positive gastric cancer |
| WEB address: | http://herceptin.com/ |
| Summary: | Find information about Herceptin® (trastuzumab), a targeted therapy for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer. Who is Herceptin for? Adjuvant Breast Cancer. Herceptin is approved for the treatment of early-stage breast cancer that is Human Epidermal growth factor Receptor 2-positive (HER2+) and has spread into the lymph nodes, or is HER2+ and has not spread into the lymph nodes. If it has not spread into the lymph nodes, the cancer needs to be estrogen receptor/progesterone receptor (ER/PR)-negative or have one high risk feature.* Herceptin can be used in several different ways: As part of a treatment course including the chemotherapy drugs doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel. This treatment course is known as 'AC-TH'. With the chemotherapy drugs docetaxel and carboplatin. This treatment course is known as 'TCH'. Alone after treatment with multiple other therapies, including an anthracycline (doxorubicin)-based therapy (a type of chemotherapy). *High risk is defined as ER/PR-positive with one of the following features: tumor size >2 cm, age <35 years, or tumor grade 2 or 3. Metastatic Breast Cancer Herceptin has 2 approved uses in metastatic breast cancer: Herceptin in combination with the chemotherapy drug paclitaxel is approved for the first line treatment of Human Epidermal growth factor Receptor 2-positive (HER2+) metastatic breast cancer. Herceptin alone is approved for the treatment of HER2+ breast cancer in patients who have received one or more chemotherapy courses for metastatic disease. Gastric Cancer: Herceptin is approved, in combination with chemotherapy (cisplatin and either capecitabine or 5-fluorouracil), for the treatment of HER2+ metastatic cancer of the stomach or gastroesophageal junction (where the esophagus meets the stomach) in patients who have not received prior treatment for their metastatic disease. Important Patient Safety Information Possible Serious Side Effects With HERCEPTIN Not all people have serious side effects, but side effects with HERCEPTIN therapy are common. Although some people may have a life-threatening side effect, most do not. Your doctor will stop treatment if any serious side effects occur. HERCEPTIN is not for everyone. Be sure to contact your doctor if you are experiencing any of the following: HEART PROBLEMS These include heart problems—such as congestive heart failure or reduced heart function—with or without symptoms. The risk for and seriousness of these heart problems were highest in people who received both HERCEPTIN and a certain type of chemotherapy (anthracycline). In a study of adjuvant (early) breast cancer, one patient died of significantly weakened heart muscle. Your doctor will check for signs of heart problems before, during, and after treatment with HERCEPTIN. INFUSION REACTIONS, including: • Fever and chills • Feeling sick to your stomach (nausea) • Throwing up (vomiting) • Pain (in some cases at tumor sites) • Headache • Dizziness • Shortness of breath These signs usually happen within 24 hours after receiving HERCEPTIN. Be sure to contact your doctor if you: Are a woman who could become pregnant, or may be pregnant HERCEPTIN may result in the death of unborn baby and birth defects. Birth control should be used while receiving HERCEPTIN after your last dose of HERCEPTIN. If you are exposed to HERCEPTIN during pregnancy or within 7 months of becoming pregnant, you are encouraged to enroll in the MotHER Pregnancy Registry by contacting 1-800-690-6720 or visiting http://www.motherpregnancyregistry.com/ and report HERCEPTIN exposure to Genentech at 1-888-835-2555. Have any signs of SEVERE LUNG PROBLEMS, including • Severe shortness of breath • Fluid in or around the lungs • Weakening of the valve between the heart and the lungs • Not enough oxygen in the body • Swelling of the lungs • Scarring of the lungs Your doctor may check for signs of severe lung problems when he or she examines you. Have LOW WHITE BLOOD CELL COUNTS Low white blood cell counts can be life threatening. Low white blood cell counts were seen more often in patients receiving HERCEPTIN plus chemotherapy than in patients receiving chemotherapy alone. Your doctor may check for signs of low white blood cell counts when he or she examines you. Other Important Information Before taking HERCEPTIN, you must have a HER2 test to determine if your cancer is HER2-positive. This is because the benefit of treatment with HERCEPTIN has been shown only in patients whose tumors are HER2-positive. Side Effects Seen Most Often With HERCEPTIN Some patients receiving HERCEPTIN for breast cancer had the following side effects: • Fever • Feeling sick to your stomach (nausea) • Throwing up (vomiting) • Infusion reactions • Diarrhea • Infections • Increased cough • Headache • Feeling tired • Shortness of breath • Rash • Low white and red blood cell counts • Muscle pain Some patients receiving HERCEPTIN for metastatic stomach cancer had the following side effects: • Low white blood cell counts • Diarrhea • Feeling tired • Low red blood cell counts • Swelling of the mouth lining • Weight loss • Upper respiratory tract infections • Fever • Low platelet counts • Swelling of the mucous membranes • Swelling of the nose and throat • Change in taste You should contact your doctor immediately if you have any of the side effects listed above. You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1–800–FDA–1088 or http://www.fda.gov/medwatch. You may also report side effects to Genentech at 1–888–835–2555. Please see additional select Important Safety Information throughout, and the full Prescribing Information, including Boxed WARNINGS. |
<title> | HER2+ Breast Cancer Treatment with Herceptin® (trastuzumab) |
| Hosting information: | Click here for more hosting information |
| Size of HTML code: | -18,392 bytes compared to average |
| Total number of links: | -61 links compared to average |
| Load time: | -0.03590565 seconds compared to average |
| Website: | herceptin.com |
|---|---|
| Most recent position: | 959,585 reached on February 11, 2014 (3,737 days ago) |
| Times found in Alexa list: | 7 |
| Average position: | 965,375 |
| All time highest position: | 959,585 reached on February 11, 2014 (3,737 days ago) |
| All time lowest position: | 970,268 reached on February 9, 2014 (3,739 days ago) |
This table shows websites that use 72.34.128.114 (trastuzumab.net) for hosting:
| List of websites | IP address and hostname |
|---|---|
| 72.34.128.114 trastuzumab.net |
Note: The matching part of IP address is marked with this style.
| Website: | herceptin.com |
|---|---|
| Most recent position: | 267,053 reached on February 6, 2014 (3,742 days ago) |
| Times found in quant list: | 156 |
| Average position: | 398,754 |
| All time highest position: | 266,563 reached on January 15, 2014 (3,764 days ago) |
| All time lowest position: | 552,825 reached on November 22, 2013 (3,818 days ago) |
There are 291 alternatives to herceptin.com
We believe that these mistakes can be made in the typing process of "herceptin.com":
No data about herceptin.com being in dropped domains database...